Intra-maxillary Molecular Releasing and its Application in the Assistance of Neurodegenerative Disease Therapeutics
Journal Title: International Journal of Clinical Therapeutics and Diagnosis (IJCTD) - Year 2016, Vol 4, Issue 1
Abstract
Neurodegenerative disease (ND) is a complex concept involves multiple pathogenesis including neuronal demyelination, apoptosis under oxidative stress, neuroinflammation with further cortical and spinal atrophy, which may lead to cognition impairment and multiple neural dysfunctions. It may present as a chronic and irreversibly progressive disorder and shows the common pathological pictures among its various types including Alzheimer’s disease (AD), Parkinson’s disease (AD), Huntington’s disease (HD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS). The symptoms often occur among the elderly above 50 years old and last from years to decades. Such facts lead ND as the highest priority to geriatrics and its related medical care. Due to its chronic progressively characteristics, regularly invasive procedure arrangements may face the difficulty and regarded as unbearable in the clinical practice. Unfortunately, current available therapy is mainly on symptom relief and the potential therapeutic targets may focus on the macromolecules including oligomer, peptides, or even functional proteins with the quaternary structure since multiple proteinopathy involvement in ND pathogenesis. Such macromolecular administrations cause the challenges in the routine drug delivery selections due to the impossibility of the traditional oral intake. Intra-maxillary molecular releasing is a newly drug delivery pathway via dental implant and may directly reach the inside bone marrow. It presents the advantages in long-term and continuous macromolecular releasing with relative painless process, which is appropriate for further applications in ND therapeutics. The stability of dental implant inside the oral cavity has also been proved for decades among more than millions around the world. However, such delivery pathway is currently under development and further interdisciplinary investigations are needed including therapeutics, pharmacokinetics, neurology, molecular biology, clinical dentistry, chemical engineering, automatics and further complementary metal-oxidesemiconductor (CMOS) technology to ensure the efficiency and prove the safety concern.
Authors and Affiliations
Yu-Jung Li
Keywords
Related Articles
- EP ID EP202965
- DOI 10.19070/2332-2926-1600021
- Views 163
- Downloads 0
Hungry Bone Syndrome Associated with Transient Hypoparathyroidism
We report on an infant who presented at 50 days old of age with hypocalcemic seizure, who proved to have transient hypoparathyroidism, biochemically. During the course of his therapy, he developed severe hungry bone synd...
Picroside II Diminishes Oxidative Stress Induced By Cerebral Ischemic Injury In Rats
Objective: To optimize the therapeutic dose and time window of picrosede II in cerebral ischemic injury in rats by orthogonal test. Methods The forebrain ischemia model was established by a bilateral common carotid arter...
The Impact of Contemporary Neurotechnology on Diagnosing and Treating Patients with Disorders of Consciousness - A Review
Disorders of consciousness, especially Vegetative State, are assessed from a theoretical (historical and ethical) and empirical (neuroscientific) points of view, through a review of the most relevant recent literature. B...
Why nursing care is missed?
Why nursing care is missed?
Medico-Legal Evaluation of Sudden Cardiac Deaths in Albania, 2014-2015
Sudden cardiac death is an occurrence of extreme severity, with medical, legal, social and public health implications. We have studied the forensic registers with regard to sudden deaths due to heart disease during the y...